Madrigal Pharmaceuticals, Inc. (MDGL)
- Sector
- Biotechnology
- Last price
- $431.70
- As of
Kresmion compiles this page from MDGL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
MADRIGAL PHARMACEUTICALS, INC. (MDGL): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-12.
See the full MDGL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MDGL on one page. Preview it with sample data, then open it live with a free account.
Preview the MDGL dossierActive events for MDGL
- high13F: funds added
7 tracked funds increased MDGL this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +118% to MDGL (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +102% to MDGL (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +1077% to MDGL (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 51% of MDGL (2026Q2)
FREE, NO ACCOUNT
Every event on MDGL, as it fires
You are seeing 5 of 22 events recorded on MDGL since 2026-06-02.
The five above landed across 2 days. The other 17 were recorded on 3 other days. 16 of the 22 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
MDGL positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| CITADEL ADVISORS LLC FundCUSIP 558868105 · 2026Q2 | $272.4M | 0.16% |
| Point72 Asset Management, L.P. FundCUSIP 558868105 · 2026Q2 | $73.6M | 0.11% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 558868105 · 2026Q2 | $43.6M | 0.03% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 558868105 · 2026Q2 | $24.7M | 0.03% |
| D. E. Shaw & Co., Inc. FundCUSIP 558868105 · 2026Q2 | $18.8M | 0.01% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 558868105 · 2026Q2 | $304K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MDGL
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on MDGL
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in MDGL on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on MDGL in the last 180 days.
Upstream: SEC EDGAR filings for MDGL
Kresmion, "MADRIGAL PHARMACEUTICALS, INC. (MDGL) institutional holdings and SEC filings", data as of 2026-09-06, https://kresmion.com/research/MDGL. Upstream data: SEC EDGAR filings for MDGL.
Link to this data (HTML):
<a href="https://kresmion.com/research/MDGL">MADRIGAL PHARMACEUTICALS, INC. (MDGL) institutional holdings and SEC filings (Kresmion)</a>
Follow MDGL on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to MDGL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.